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ABSTRACT 
Gene therapy, which involves the transfer of nucleic acid into target cells in patients, has 
become one of the most important and widely explored strategies to treat a variety of diseases, 
such as cancer, infectious diseases and genetic disorders. Relative to viral vectors that have high 
immunogenicity, toxicity and oncogenicity, non-viral vectors have gained a lot of interest in recent 
years. This is largely due to their ability to mimic viral vector features including the capacity to 
overcome extra- and intra-cellular barriers and to enhance transfection efficiency. 
Polyethyleneimine (PEI) has been extensively investigated as a non-viral vector. This cationic 
polymer, which is able to compact nucleic acid through electrostatic interactions and to transport it 
across the negatively charged cell membranes, has been shown to effectively transfect nucleic acid 
into different cell lines. Moreover, entrapment of gold nanoparticles (Au NPs) into such an 
amine-terminated polymer template has been shown to significantly enhance gene transfection 
efficiency. 
In this work, a novel non-viral nucleic acid vector system for enhanced and targeted nucleic 
acid delivery applications was developed. The system was based on the functionalization of PEI 
with folic acid (FA; for targeted delivery to cancer cells overexpressing FA receptors on their 
surface) using polyethylene glycol (PEG) as a linker molecule. This was followed by the 
preparation of PEI-entrapped Au NPs (Au PENPs; for enhancement of transfection efficiency). In 
the synthesis process, the primary amines of PEI were first partially modified with fluorescein 
isothiocyanate (FI) using a molar ratio of 1:7. The formed PEI-FI conjugate was then further 
modified with either PEG or PEGylated FA using a molar ratio of 1:1. This process was finally 
followed by entrapment of Au NPs into the modified polymers. The resulting conjugates and Au 
PENPs were characterized by several techniques, namely Nuclear Magnetic Resonance, Dynamic 
Light Scattering and Ultraviolet-Visible Spectroscopy, to assess their physicochemical properties. 
In the cell biology studies, the synthesized conjugates and their respective Au PENPs were 
shown to be non-toxic towards A2780 human ovarian carcinoma cells. The role of these materials 
as gene delivery agents was lastly evaluated. In the gene delivery studies, the A2780 cells were 
successfully transfected with plasmid DNA using the different vector systems. However, 
FA-modification and Au NPs entrapment were not determinant factors for improved transfection 
efficiency. In the gene silencing studies, on the other hand, the Au PENPs were shown to 
effectively deliver small interfering RNA, thereby reducing the expression of the B-cell lymphoma 
2 protein. Based on these results, we can say that the systems synthesized in this work show 
potential for enhanced and targeted gene therapy applications. 
Keywords: Polyethyleneimine; Gold Nanoparticles; Gene Delivery; Gene Silencing; Targeting. 
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RESUMO 
A terapia génica consiste na transferência de ácidos nuleicos para células alvo, e é 
considerada uma das estratégias mais importantes no tratamento de diversas doenças (ex. cancro, 
doenças infeciosas e distúrbios genéticos). Ao contrário dos vetores virais que têm alta 
imunogenicidade, toxicidade e atividade oncogénica, os vetores não-virais têm vindo a ganhar 
notoriedade nos últimos anos. Isto deve-se, em grande parte, à sua capacidade de mimetizar 
características de vetores virais, como por exemplo a capacidade de superar as barreiras extra e 
intracelulares e aumentar a eficiência de transfecção. A polietilenimina (PEI) tem sido 
extensivamente estudado por ser um vetor não-viral. Este polímero catiónico é eficaz na 
transfeção de diferentes linhas celulares, pois possui a capacidade de condensar os ácidos 
nucleícos através de interações eletrostáticas e de transportá-los através da membrana celular. 
Diferentes estratégias têm sido utilizadas para aumentar a eficiência de transfeção deste polímero. 
A redução de iões de ouro para formação de nanopartículas (Au NPs) no interior deste e outros 
polímeros semelhantes (com aminas terminais), demonstraram um aumento significativo na 
eficiência da transfeção de genes por parte destes. 
Neste trabalho, foram preparados sistemas de entrega de genes baseados no polímero PEI. 
Este foi funcionalizado com  ácido fólico (FA) (para entrega específica em células cancerígenas 
alvo, com elevada expressão de recetores FA à superficie) utilizando polietilenoglicol (PEG) como 
molécula ligante. Em seguida procedeu-se à formação de Au NPs no seu interior (para aumento da 
eficiêcia de transfeção). No processo da síntese, isotiocianato de fluoresceína (FI) foi 
primeiramente ligado às aminas terminais do PEI (razão de 1:7), dando origem a PEI-FI. De 
seguida, cadeias de polietilenoglicol (PEG) ou polietilenoglicol-ácido fólico (PEG-FA) foram 
conjugadas ao PEI-FI (razão de 1:1), obtendo-se assim os sistemas finais  PEI-FI-mPEG e 
PEI-FI-(PEG-FA). Num passo final, estes sistemas serviram como matriz durante a formação das 
Au NPs no seu interior. Estes sistemas foram caracterizados por Ressonância Magnética Nuclear, 
Dispersão Dinâmica de Luz e por espectroscopia de Ultravioleta-Visível para verificar as suas 
propriedades físico-químicas. 
Estudos in vitro foram realizados utilizando células de carcinoma do ovário humano (A2780). 
Estes revelaram que os sistemas PEI-FI-mPEG e PEI-FI-(PEG-FA) (com e sem Au NPs) não 
apresentavam toxicidade. Nos ensaios de entrega de genes, as células A2780 foram transfetadas 
com sucesso com ADN plásmidico utilizando os diferentes vetores. No entanto, a modificação 
com FA e a presença de Au NPs não foram factores determinantes para a melhoria da eficiência de 
transfeção. Por outro lado, os estudos de silenciamento dos genes utilizando pequenos fragmentos 
de ARN, demonstraram que, os compostos com Au NPs foram capazes de reduzir a expressão da 
bcl-2, uma proteína presente em células do cancro. Com base nestes resultados, os compostos 
sintetizados durante este trabalho poderão ser considerados sistemas promissores para aplicações 
de terapia génica  direcionada. 
Palavras-chave: Polietilenimina; Nanopartículas de Ouro; Entrega de Genes; Silenciamento 
Gênico; Terapia Direcionada.  
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CHAPTER 1 – INTRODUCTION 
1.1 Nucleic acid delivery 
Gene therapy, the transfer of genetic agents into target cells in patients, has 
become one of the most important and widely explored strategies to treat a variety of 
diseases, such as cancer, infectious diseases and genetic disorders. Generally, gene 
therapy is divided into two categories: gene delivery that is the expression of specific 
proteins through plasmid DNA (pDNA) and gene silencing that is the repression of 
gene products through small interfering RNA (siRNA). Unlike most peptide and 
protein delivery systems, nucleic acid delivery systems must deliver nucleic acids to 
the cytoplasm or to the nucleus of cells. This unique requirement is one of the most 
significant challenges for applications, since nucleic acid is susceptible to hydrolytic 
and enzymatic degradation in the body and is not capable of passing through the cell 
membrane.
1
 But it is addressed by using different methods, such as, physical methods, 
attenuated viral delivery vectors and non-viral delivery vectors. These methods with 
the respective advantages and disadvantages have great therapeutic potential in a 
variety of different clinical applications.  
1.1.1 Gene delivery 
Gene delivery is the process of transferring exogenous DNA into host cells for 
different applications, such as gene therapy and genetic research. After its transfer, the 
exogenous DNA is translated intracellularly to specific proteins to perform the 
corresponding function. Currently, the methods of gene delivery can be divided into 
three categories: physical methods, non-viral vectors and viral vectors.
2
 
Physical methods of gene delivery usually use a physical force to transiently 
penetrate the membrane barrier of the cells and to promote intracellular gene 
transfection. These physical forces include electrical, hydrodynamic, mechanical, 
magnetic and ultrasonic energy.
2
 Compared to non-viral and viral vectors, physical 
methods are very simple, non-immunogenic and display relatively low cytotoxicity, 
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since the genes are directly delivered into the cytoplasm and nucleus of the cells 
without any substances that have immunogenic or cytotoxic properties.
3
 Physical 
methods include naked DNA, electroporation, magnetofection, sonoporation and 
photoporation. 
Electroporation is achieved through short electric pulses that temporarily 
destabilize the cell membrane, generating pores that allow any genes that surround the 
membrane to penetrate into the cell cytoplasm.
4-5
 A limitation to this technique is that 
the number of transfected cells is few. The parameters of electric pulse, such as, 
frequency, duration and intensity, can influence gene stability and can induce cell or 
tissue injury and consequently affect transfection efficiency.
6
 
Magnetofection employs a magnetic field and magnetic nanoparticles (NPs) to 
facilitate gene transfection. These magnetic NPs, which consist of iron oxide coated 
with cationic materials, can be complexed with nucleic acids through electrostatic 
interactions. The external magnetic field induces rapid concentrating of the magnetic 
particles on the target cells.
7-8
 After the cellular uptake of nucleic acids by endocytosis 
and pinocytosis, the magnetic nanoparticles release the nucleic acids into the 
cytoplasm of the cell through one of several mechanisms which are dictated by the NP 
composition.
9-10
 Important advantages of magnetofection include the localized 
delivery of nucleic acids to specific areas under the influence of a magnetic field and 
the improved kinetics of gene transfection even at low dosage.
3
 
The sonoporation method utilizes ultrasounds as a physical force to temporarily 
permeabilize the cell membrane. The resultant formation of pores in the membrane 
facilitates the cellular uptake of nucleic acids. The parameters of ultrasound, such as, 
pulse frequency, intensity and duration, as well as the size of the nucleic acid, all play 
an important role in transfection efficiency.
11-12
 Although low transfection efficiency 
is a disadvantage of this method, the use of ultrasounds is less violent and more 
comfortable. Thus, it is considered as the preferred physical delivery method for in 
vivo applications.
3
 
Photoporation utilizes the femtosecond infrared or near-infrared laser beam to 
transiently generate some pores in the cell membrane to enhance gene delivery 
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without any risk of tissue damage.
13-14
 Laser density and duration of laser treatment 
are critical parameters that improve the transfection efficiency of nucleic acids, while 
a relatively unfocused laser can be used to minimize tissue damage and maximize the 
transfected area.
13
 
Compared to the physical methods and non-viral vectors, viral vectors exhibit 
relatively high delivery efficiency, especially for gene delivery in vivo. This is because 
viral vectors take advantage of the natural characteristics of viruses to efficiently carry 
their genome into cells and to navigate into the nucleus. To date, viral vectors include 
adenovirus, retrovirus, adeno-associated virus, herpes simplex virus, foamy virus, 
poxvirus and lentivirus. These can be divided into two categories: RNA virus vectors 
and DNA virus vectors.
15
 RNA virus vectors are able to perform permanent transgene 
expression through gene integration,
16-17
 while DNA virus vectors can perform 
temporary transgene expression in the episomal form without gene integration.
18
 Viral 
vectors, which are different from viruses, are replication deficient viruses that contain 
the gene sequence of interest but no pathogenic gene sequence from their genome 
thereby strengthening their safety.
19
 But viral vectors still have several problems 
limiting their applications, for example, immunogenicity, toxicity, side effects in 
non-targeted cells and costs in production. 
1.1.2 Gene silencing 
RNA interference (RNAi), an evolutionary conserved gene-silencing mechanism, 
was discovered in 1998.
20
 This procedure employs RNA as the therapeutic agent to 
carry out RNA silencing that can protect genomes from endogenous and exogenous 
gene threats and that can control gene expression in cells.
21
 Since RNAi possesses 
ease of manipulation, great specificity and efficiency of gene silencing, it has become 
a popular and powerful tool for therapeutic applications. Moreover, extensive research 
in gene delivery has resulted in the development of gene delivery methods and vectors, 
which offer great potential for the recently emerging gene silencing strategy in which 
siRNA is delivered intracellularly.
22
 Unlike physical methods but similar to DNA 
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vectors, siRNA vectors can be classified as either viral or non-viral.
23
 Compared to 
non-viral vectors, viral vectors have great silencing efficacy, but their disadvantages, 
such as immunogenicity, safety and cost limit their development. Non-viral vectors 
such as cationic polymers and cationic lipids have been designed and synthesized to 
enhance silencing efficiency. What is more, relative to DNA vectors, siRNA vectors 
are not required to deliver siRNA into the nucleus but only into the cytoplasm. After 
delivery into the cytoplasm, siRNA can be used to perform gene silencing.  
In the general process of gene silencing (Figure 1), long double-stranded RNA 
molecules are cleaved into 21-23 siRNA nucleotide fragments by the endogenous 
RNaseIII-like enzyme, Dicer.
24
 The resulting siRNA molecules are incorporated into 
the RNA-induced silencing complex (RISC), which includes proteins necessary for 
unwinding the siRNA as well as binding and cleaving the target messenger RNA 
(mRNA).
25
 After activation of the formed RISC-siRNA complex, the siRNA is 
unwrapped and one of the two strands is released, consequently leading to the 
formation of the RISC complex with a single RNA strand. The activated RISC-RNA 
complex binds to the homologous target mRNA by specific base-pair recognition, 
resulting in the sequence-specific degradation of mRNA and finally the knock-down 
of the expression of the corresponding protein. 
 
Figure 1 The mechanism of RNAi. (Figure adapted from Ref. 26) 
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1.1.3 Delivery mechanism of non-viral vectors 
In nucleic acid delivery systems, there are a variety of both extracellular and 
intracellular barriers, which decrease the probability of nucleic acid entry into the 
cytoplasm or the nucleus. The extracellular barriers include degradation by nucleases, 
non-specific interaction with biomacromolecules, uptake by the reticuloendothelial 
system (RES), renal excretion and diffusion from the extracellular matrix to the cell 
surface. Several hurdles must be overcome in the intracellular aspect including 
cellular binding, uptake and internalization, lysosomal degradation, as well as nuclear 
localization.
1, 22
 
As efficient vectors, viruses can overcome the above barriers, through different 
functions, for example, protection of nucleic acid, intracellular and extracellular 
transport, endolysosomal escape, internalization and targetability. By imitating virus 
features, non-viral vectors have been rationally designed to overcome these barriers 
and to achieve the goal of effective nucleic acid delivery for enhanced efficiency.
1
 The 
delivery mechanism of non-viral vectors for gene delivery and gene silencing are 
simply described and compared below. 
Due to the anionic property of nucleic acids (DNA and RNA), non-viral vectors 
should be cationic in nature in order to bind and condense the nucleic acid by 
electrostatic interaction to form compact complexes.
27
 An excessively cationic vector 
is required to neutralize the negative charge of the nucleic acid and to form the 
positive complexes. The resultant complexes with net positive charge can interact 
with the negatively charged cellular membrane and can be internalized into the cells 
through different pathways (e.g., receptor mediated endocytosis or adsorptive 
endocytosis) as shown in Figure 2. After cellular uptake, the siRNA can directly 
escape from the endosomal compartment and then perform gene silencing. In the case 
of DNA, during maturation of the endosome to a lysosome, the nucleic acid is easily 
degraded by enzymes in the acidic environment. Here, not only can the cationic 
vector protect the DNA from degradation but it can also facilitate the escape of the 
polyplexes from the endosomal or lysosomal compartments through a mechanism,  
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Figure 2 Representative scheme of nucleic acid delivery. RISC: RNA-induced silencing complex; 
siRNA: small interfering RNA; mRNA: messenger RNA. (Figure adapted from Ref. 28) 
 
such as the proton sponge effect.
29
 After arriving at the cytoplasm, the polyplexes start 
to move towards the nucleus through passive diffusion or a nuclear translocation 
process.
30-32
 Finally, after the DNA is released from the polyplexes into the nucleus, 
transcription and translation are carried out to express the targeted proteins. 
1.1.4 Targeted nucleic acid delivery 
In order to enhance the concentration of nucleic acid at the site of action and to 
spare widespread toxicity at non-target sites, active and passive targeting strategies 
have become more essential in clinical applications. 
Due to the specific physiology of organs or tissues, as well as the properties of 
the vectors, the tendency of complexes to accumulate in a specific organ has been 
used as a passive targeting strategy. This process is commonly influenced by the size 
and surface features of the complexes.
33
 It has been shown that complexes larger than 
100 nm are easily taken up by the RES and then accumulated in the spleen, while 
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complexes less than 10 nm in size are easily eliminated by the kidneys. Complexes of 
10-100 nm, particularly those smaller than 70 nm, tend to accumulate in the liver 
through fenestrated capillaries. Complexes smaller than 200 nm in size effectively 
accumulate in solid tumors through prolonged circulation time and the enhanced 
permeability and retention effect, which depends on the leaky nature of the tumor 
vasculature.
1, 34
 
Compared to viral vectors, non-viral vectors lack cellular binding and 
internalization selectivity. To overcome this limitation, a variety of moieties that target 
specific tissues or cells can be conjugated onto the non-viral vectors. Moieties such as 
folic acid (FA),
35
 mannose,
36
 galactose,
37
 integrin-binding peptide,
38
 transferrin,
39
 
antibodies,
40
 vitamins
41
 and aptamers
42
 have been shown to enhance cellular uptake 
efficacy in certain cells or tissues, including dendritic cells,
36
 cardiovascular tissue,
43
 
skeletal muscle
44
 and airway epithelium
45
. Moreover, these moieties have been shown 
to decrease the potential side effects associated with the vectors in other tissues or 
cells.
46
 Compared with other targeting moieties, antibodies possess distinct 
advantages, such as, high affinity, high specificity and flexibility in selectivity. 
However, as these moieties are biological macromolecules, they may produce an 
immunogenic response. Thus, if receptors are overexpressed on the target cells, the 
use of small molecules as targeting moieties is a judicious choice.
47
 
In gene delivery, the nuclear envelope is one of the intracellular barriers that 
must be overcome by non-viral vectors. As pDNA is unable to passively diffuse 
through the nuclear pore complex, nuclear entry can occur via two major routes. The 
first is through passive nuclear importation during mitosis, where the nuclear 
membrane temporarily breaks down; while the second route of nuclear entry can 
occur via active transport through the nuclear pore complex.
48
 Whether nuclear entry 
of polyplexes with polyethylenimine (PEI) relies on cell division is under debate.
49-55
 
For gene delivery of PEI-based polyplexes in nondividing cells, the transport of 
pDNA from the cytoplasm into the nucleus can be improved by electrostatically 
complexing or covalently conjugating the nuclear targeting function of synthetic 
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nuclear localization sequence (NLS) peptides,
56
 ketalization
57
 and oligosaccharides
58
 
onto the polymer. In the case of nuclear targeting using gold nanoparticles (Au NPs), 
conjugation with NLS peptides has also proved to be a successful strategy.
59
 Au NP 
constructs made up of nucleolin-specific aptamers and gold nanostars have also been 
shown to be actively transported to the nucleus via nuclear envelope invaginations, 
resulting in major changes in nuclear phenotype and increasing therapeutic efficacy.
60
 
More recently, the size-dependent intranucleus delivery of ultrasmall Au NPs (smaller 
than 10 nm) was reported as a novel strategy for nucleic acid delivery.
61
 Moreover, 
studies have indicated that PEI-capped Au NPs may be used as nuclear-targeting 
vectors for gene delivery.
62
 
1.2 Non-viral vector systems 
In gene therapy applications, the simplest approach is to use the “naked” gene 
without any carriers. However some problems, such as little uptake by the cells, 
speedy degradation by the nucleases and rapid clearance from the plasma, have 
limited the development of this approach. In order to overcome these problems, as 
well as those associated with the physical methods and viral vectors discussed in 
Section 1.1, non-viral vectors provide an attractive alternative approach. For a 
desirable non-viral vector, several requirements should be met. The vector should be 
able to (1) prevent degradation of the nucleic acid during systemic circulation, (2) 
efficiently deliver the nucleic acid to the target site, (3) facilitate the cellular uptake 
and endosomal escape of the nucleic acid, and (4) either release siRNA to the cellular 
RNAi machinery or release pDNA to the nucleus.
63
 Moreover, the non-viral vector 
should be non-immunogenic, non-pathogenic, non-toxic, inexpensive, easily 
administrable and stable.
27
 
The majority of non-viral vectors can be divided into cationic lipids and cationic 
polymers, whose complexes with pDNA are known as lipoplexes and polyplexes, 
respectively. Cationic lipids used as gene delivery vectors were first reported in 1987 
by Felgner.
64
 Cationic lipids have relatively high efficiency and a wide range of 
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applications. However, disadvantages, such as low reproducibility, instability and 
toxicity, are particularly outstanding and limit their applications. Cationic polymers, 
such as PEI, chitosan, dendrimer and poly(L-lysine), have been widely studied, but 
high cytotoxicity and low transfection efficiency are properties that have lowered their 
potential use in clinical applications.
65
 On this basis, smart cationic polymers with 
desirable properties have been designed and synthesized as non-viral gene delivery 
vectors, which are chemically stable in the extracellular environment and are rapidly 
degradable in the intracellular environment.
1, 66
 Additionally, inorganic materials with 
multifunctional properties have also been exploited as novel non-viral vectors for 
gene therapy (e.g. Au NPs, carbon nanotubes, quantum dots, superparamagnetic iron 
oxide NPs and silica).
67
  
1.2.1 PEI 
PEI was investigated as a versatile synthetic vector for gene and oligonucleotide 
transfection in 1995,
29
 and has since been one of the most commonly and popularly 
employed non-viral cationic nucleic acid vectors with superior transfection 
consistency and efficiency both in vitro and in vivo.
28, 68
 As a high charge density 
polycation, PEI has repeating units in which there is a protonable amino-nitrogen in 
every three atoms. Typically, PEI can be divided into three types: linear PEI, branched 
PEI and PEI dendrimer, as shown in Figure 3. Linear PEI contains all secondary 
amines only. In contrast, branched PEI contains not only primary and secondary 
amines, but also tertiary amines, two-thirds of which are protonated under 
physiological conditions. The remaining unprotonated tertiary amines of branched 
PEI have different pKa values that confer a large buffering capacity (representing the 
percentage of amino groups that become protonated from pH 7.4 to 5.1).
29, 69
 This 
property of high buffering capacity at low pH led to the proton sponge hypothesis 
proposed by Behr in 1997,
70
 in which as PEI molecules are pumped into the 
endosomes, more protons than unprotonated amines of the polymer absorbed are also 
pumped into and increase the massive influx of chloride ions and water into the 
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endosomes. The cooperative effect of osmotic swelling and the swelling of PEI 
induced by the steric repulsion between protonated amines induces endosomal 
membrane rupture, facilitating the escape of the polyplexes from the endosomal 
compartment to the cytoplasm during the maturation of the endosome into a 
lysosome.
70-71
 Thus, buffering capacity is one of the most important parameters that 
can be used to evaluate the ability to mediate endosomal escape. More recently 
however Benjaminsen et al. pointed out that PEI does not induce the change in 
lysosomal pH value and it is unlikely that the proton sponge effect is the principal 
mechanism of polyplex release.
72
 
 
Figure 3 Schematic illustration of the structure of (a) linear PEI fragment, (b) typical branched PEI 
fragment and (c) PEI dendrimer generation 4. (Figure adapted from Ref. 73) 
 
As a nucleic acid non-viral vector, PEI has an inherent disadvantage in that it is 
highly cytotoxic in vitro. There are two kinds of cytotoxicity mechanisms during the 
PEI mediated transfection procedure.
74-75
 In the first mechanism, the cellular 
membrane may be destabilized by free PEI, which results in necrosis-related 
cytotoxicity. The removing of free PEI from the polyplexes may lead to a decrease in 
their cytotoxicity.
76
 In the second mechanism, free intracellular PEI that is 
dissociating from the polyplexes can bind to the negatively charged mitochondrial 
membrane, which leads to harmful cellular apoptosis. If PEI can be degraded into 
small pieces in the cell, the cytotoxicity induced by PEI could be decreased. Moreover, 
the molecular weight of PEI has an influence on cytotoxicity and transfection 
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efficiency. Compared to high molecular weight PEI, low molecular weight PEI 
possesses inferior cytotoxicity and lower transfection efficiency.
77
 
A compromise between cytotoxicity and transfection efficiency is one of the 
primary parameters that should be taken into account. Generally, the conjugation of 
poly(ethylene glycol) (PEG) onto PEI is a useful method to produce PEGylated PEI 
with lower cytotoxicity, lower aggregation and higher stability.
78
 Although PEGylated 
PEI shows lower cytotoxicity and has a positive surface charge to compact pDNA to 
form polyplexes, PEGylation usually decreases transfection efficiency. This is 
because PEGylation not only decreases the surface charge of the polyplexes thereby 
attenuating cellular internalization and endosomal escape of polyplexes,
79
 but it also 
forms a distinct hydrated layer which is a result of the steric shielding effect of PEG.
80
 
In order to attain the best compromise, the molecular weight of PEI and PEG and the 
ratio between them should be optimized. Besides PEGylation, attempts have been 
made to reduce the cytotoxicity of PEI through other modifications of its primary 
amines, for example, N, N-dimethylaminoethl methacrylate,
81
 dextran,
82
 cationic 
lipid,
83
 cystamine derivatives
84
 and N-isopropylacrylamide.
85
 
1.2.2 Au NPs 
Currently, nanotechnology is considered to hold great promise in the 
development of novel agents for various biomedical applications. In fact, it is an 
active field in which numerous nanomaterials including nanoparticles, nanotubes, 
nanorods and nanowires can be obtained by “top-down” or “bottom-up” approaches. 
Nanoparticles, particles with a diameter of 1 to 100 nm in two or three dimensions, 
have attracted a lot of attention. Au NPs in particular possess significantly useful 
characteristics, such as a high surface-to-volume ratio, size- and shape-dependent 
properties, ease of surface functionalization, low cytotoxicity and remarkable 
biocompatibility. These NPs exhibit a wide range of excellent physical and chemical 
properties, for example, surface-enhanced raman scattering, surface plasmon 
resonance, fluorescence quenching, magnetic resonance, redox activity and catalytic 
activity, all of which are different from those of the same bulk material or atom.
86-88
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Surface plasmon resonance in particular results in the unique optical properties of Au 
NPs, a feature that forms the basis of several biomedical applications and that can be 
tailored by varying the shape or size of Au NPs.
89
 The size distribution and 
morphology of Au NPs can be analyzed and characterized by using different 
analytical techniques, for example, ultraviolet–visible (UV-Vis) spectroscopy, 
dynamic light scattering (DLS), X-ray diffraction, small-angle X-ray scattering, 
electron microscopy, scanning probe microscopy and mass spectroscopy.
90
 
Based on distinct properties discussed above, Au NPs have been applied in 
several medical and biological fields including targeted delivery of small- and 
macro-molecular drugs, biosensors, immunoassays, bioimaging of cells and tissues, 
detection and photothermal therapy of cancer cells and microorganisms (Figure 4). In 
order to achieve the synergistic effects of the properties of Au NPs and the function of 
capping ligands, multi-functional capping ligands have been loaded onto Au NP 
surfaces through non-covalent conjugation (i.e., hydrophobic interactions, 
electrostatic interactions and specific binding affinity) and covalent conjugation (i.e., 
thiolation, click chemistry reaction and amine-carboxylate binding).
91-96
 This 
synergistic effect makes Au NPs significantly versatile for biomedical applications. As 
a non-viral vector, Au NPs have attracted much attention because of their low toxicity, 
bio-inertness, ease of synthesis and ease of surface modification. 
 
Figure 4 Scheme for the biomedical applications of Au NPs. (Figure adapted from Ref. 97) 
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1.2.2.1 Classical synthesis of Au NPs 
Au NPs have been successfully synthesized for different applications using 
applied methods, such as sonolysis, laser radiation, chemical reduction and gas 
condensation. But in medical and biochemical applications, Au NPs are supposed to 
be soluble in aqueous solution. Thus, chemical reduction is considered to be the most 
important and appropriate synthesis method. 
One of the most popular synthesis methods for preparing Au NPs is called the 
Turkevich method that was developed by Turkevich et al. in 1951.
98
 In this method, 
hydrogen tetrachloroaurate (HAuCl4) in boiling water is treated with citric acid, which 
not only reduces the gold ions to atoms but also stabilizes the colloidal Au NPs. Frens 
further improved this method by changing the relative amounts of the gold/citrate 
reactants, in order to control the size distribution of the Au NPs through adjusting the 
relative rates of the two independent processes of nucleation and growth of the Au 
NPs.
99
 These citrate-stabilized Au NPs have been used as tunable foundational 
materials for a variety of applications, since the ligand exchange of functionalized 
thiols for them was carried out.
100
 In the process of the exchange of the thiolate ligand, 
several agents, including Tween 20
101
 and thioctic acid,
102
 have been successfully 
used to overcome the irreversible aggregation of electrostatically stabilized NPs in 
water. 
In 1994, Brust et al.
103
 created a novel one-step method for the preparation of 
unusual Au NPs by combining a two-phase approach
104
 and monolayer self-assembly 
with alkane thiols.
105-106
 Here, AuCl4
-
 was transferred from water to toluene by using 
the phase-transfer reagent tetraoctylammonium bromide and was then reduced with 
sodium borohydride (NaBH4) in the presence of the thiol capping ligand 
dodecanethiol, resulting in surface reaction in both nucleation and growth of Au NPs. 
In this simple method for the direct synthesis of surface-functionalized Au NPs, the 
reaction conditions can be changed to fabricate low dispersity Au NPs with core 
diameters of 1.5 to 5.2 nm. Also, owing to both the strong gold-thiol interactions and 
CHAPTER 1 - INTRODUCTION 
16 
 
the van der Waals attractions between the neighboring ligands, these Au NPs possess 
higher stability relative to others.
107-108
 
1.2.2.2 Templated synthesis of Au NPs 
Unlike the irreversible aggregation of electrostatically stabilized Au NPs in water, 
alkanethiolate-stabilized Au NPs are so stable and dispersible both in organic and 
aqueous media as a result of steric repulsion. In the spontaneous modification of 
capping ligands onto the surface of the gold core, efficient bonding interactions are 
needed. In fact, bonding between the Au atoms and organic molecules that contain 
either sulfhydryl, amine or carboxyl groups can form S-Au, N-Au or O-Au bonds, 
respectively, which play a role in stabilizing the Au NPs.
109-111
 Generally, Au NPs can 
be generated by using reducing agents. Not only may these two kinds of agents need 
different reaction conditions, but also excessive reducing ions added during the 
reducing process may not be fully removed. Based on this, templated synthesis 
methods have attracted tremendous attention to enhance the homogeneity and purity 
of the Au NPs.  
As a template, a polymer with reducing ability can be used to reduce and 
stabilize Au NPs, and even control their size and shape. This can be achieved by 
regulating the polymer structure and reaction conditions using any one of the four 
categories: nonelectrolyte homo-polymers, dendrimers, polyelectrolytes, and block 
copolymers.
112
 
As a water-soluble nonelectrolyte homo-polymer, polyvinylpyrrolidone (PVP) 
was used by Zhou et al. to synthesize extremely stable non-toxic size-controlled 
water-soluble monodispersed Au NPs.
113
 Here, sodium hydroxide was used as the 
initiator in a one-step reaction method at room temperature and the reaction reached 
completeness in several minutes.
113
 Overall, the possible reducing mechanisms of 
PVP can be divided into three categories: C=O double bond, free radical mechanism 
and the oxidation mechanism of the hydroxyl end groups.
114-117
 As shown in Figure 5,  
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Figure 5 Adsorption and cobridging of (a) PVP molecules in (b) a surface layer via Au atoms on a gold 
particle. (Figure adapted from Ref. 118) 
 
the C=O oxygen atoms of PVP can be easily attached to the surface of Au NPs 
through a strong adhesive force.
118
 Thus, PVP can be considered as an ideal stabilizer 
that protects Au NPs from agglomeration and that directs Au NPs growth. 
Dendrimers have well-defined three-dimensional molecular architectures with 
multiple surface functional groups and a low polydispersity index.
119
 As a template, 
amine-terminated poly(amidoamine) (PAMAM) dendrimers have been used to entrap 
or stabilize Au NPs,
120
 the size of which can be controlled by the gold atom/dendrimer 
ratio
121
 or the dendrimer generation.
122
 In the reaction, a slow reduction rate can be 
used to form a hybrid dendrimer-metal composite material.
123
 
Electrolyte polymers such as PEI, which have good water-solubility and 
reducing capacity, can be used to synthesize Au NPs in aqueous solution. In the 
synthesis process, the cationic polyelectrolyte PEI can be used as a stabilizer and a 
reducing agent, due to the reducing effect of its amino end groups. The molar ratio of 
PEI to Au precursors has influence on the growth of the Au NPs, resulting in the 
different sizes of the formed nanoparticles.
124-126
 The PEI-stabilized Au NPs have less 
cellular toxicity and were shown to be suitable for carrying siRNA.
127
 Compared to 
the irregular structure of PEI, the design of block copolymer structures can meet the 
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requirements necessary to improve the surface chemistry characteristics and to control 
the size and the solubility of the formed Au NPs. Moreover, by using a bottom-up 
“cage-to-framework” method, a well-defined, discrete organic molecular cage with 
pendant interior thioether groups was recently used in the controlled synthesis of Au 
NPs inside a cage cavity exhibiting a narrow size distribution (1.9 ± 0.4 nm).
128
 
1.2.3 Gold/PEI non-viral vector 
Since the limited characteristics of inorganic or polymeric materials may not 
satisfy the needs of more diverse applications, such as theranostic agents,
129
 more and 
more attention has been paid to inorganic/polymeric hybrid system in order to achieve 
the synergistic effects of the properties of inorganic materials and the functions of 
polymeric materials. For non-viral vectors, the synergistic effects may lead to a 
reduction in cytotoxicity, an increase in transfection efficiency, a targeting ability and 
the use of a low-dose.
67, 130
 For instance, Shan et al. reported
119
 that amine-terminated 
generation 5 PAMAM dendrimers were utilized as templates to synthesize Au NPs 
with different gold atom/dendrimer molar ratios (Figure 6). The formed 
dendrimer-entrapped Au NPs were demonstrated to be effective non-viral gene 
delivery vectors that possessed significantly higher gene transfection efficiency 
relative to the dendrimers without entrapped Au NPs. Entrapment of the Au NPs 
within the dendrimers helped preserve their 3-D spherical morphology resulting in a 
more efficient interaction between the dendrimers and pDNA. Moreover, these 
non-viral vectors were shown to possess the low cytotoxicity when compared with the 
native generation 5 PAMAM dendrimer.
35, 119
 
In the case of gold/PEI hybrid systems that are used as non-viral vectors, PEI has 
generally been constructed onto Au NP cores, which are known to provide an 
applicable and attractive scaffold for nucleic acid delivery.
131-132
 Au NPs can be 
synthesized with a diameter of about 5 to 150 nm and can then be modified with 
surface ligands that endow the Au NPs with specific properties.
131, 133
 In several 
defferent studies, branched PEI polymers having different molecular weights (2 kDa 
and 0.8 kDa) were conjugated onto Au NPs to form PEI-capped Au NPs.
131, 134-135
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Figure 6 Schematic illustration of the structure of (a) amine-terminated generation 5 PAMAM 
dendrimers and (b) dendrimer-entrapped Au NPs. (Figure adapted from Ref. 119) 
 
The prepared materials were all shown to exhibit high transfection efficiency, mild 
cytotoxicity and potential clinical applications as gene delivery vectors.
131, 134-135
 In 
another study it was found that by conjugating pDNA expressing short hairpin RNA 
onto similar PEI-capped Au NPs, the nuclear-targeting vector was able to 
downregulate target genes expressed in the nucleus.
62
 PEI-capped Au NPs synthesized 
using high molecular weight PEI (25 kDa) by reductive catechol chemistry or by a 
one-pot synthesis method have also been prepared and subsequently evaluated as gene 
silencing vectors.
127, 136
 These vectors, which were conjugated with monoclonal 
antibodies to endow them with targeting capabilities, displayed extremely low 
cytotoxicity and high gene silencing efficiency.
137
 PEI-capped Au NPs used as a core 
and then coated with multiple alternating layers of positively charged polyelectrolytes 
and negatively charged genes using a layer-by-layer approach, led to the development 
of vectors capable of simultaneous co-delivery of pDNA and siRNA.
130, 138
 
1.3 Objectives of the thesis 
The main objective of the present project was to develop a novel non-viral 
nucleic acid vector for enhanced and targeted nucleic acid delivery applications. The 
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system to be developed was based on the entrapment of Au NPs in PEGylated PEI, 
thereby forming Au PENPs. In the synthesis process (Figure 7), the primary amines of 
PEI were first partially modified with FI. The resulting conjugates were then either 
partially PEGylated or modified with PEGylated FA to get the PEI-FI-mPEG and 
PEI-FI-(PEG-FA) conjugates. Lastly, these conjugate systems were used as templates 
to entrap Au NPs to produce the corresponding Au PENPs. The synthesized 
conjugates, as well as their respective Au PENPs, were analyzed and characterized 
using different techniques including UV-Vis spectroscopy, DLS and nuclear magnetic 
resonance (NMR). They were then finally evaluated in vitro as non-viral vectors for 
the enhanced delivery of either pDNA or siRNA using A2780 human ovarian 
carcinoma cells that overexpress FA receptors. 
 
Figure 7 Synthesis procedures of (Au
0
)-PEI-FI-mPEG (a) and (Au
0
)-PEI-FI-(PEG-FA) (b). 
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CHAPTER 2 – MATERIALS AND METHODS 
2.1 Materials and reagents 
Branched PEI (Mw = 25 kDa), fluorescein isothiocyanate (FI), FA, NaBH4, 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide 
(NHS) and HAuCl4 were purchased from Sigma-Aldrich (MO, USA). PEG 
monomethyl ether with a carboxyl end group (mPEG-COOH, Mw = 2 kDa) and 
amine-PEG-carboxylic acid (NH2-PEG-COOH, Mw = 2 kDa) were from Shanghai 
Yanyi Biotechnology Corporation (China). Spectra/Por
®
 regenerated cellulose dialysis 
membranes (molecular weight cut-off, MWCO = 1 kDa and 10 kDa) were acquired 
from Spectrum Laboratories, Inc (CA, USA). Reporter lysis buffer (RLB) and the 
luciferase assay system were from Promega (WI, USA). The PicoGreen assay kit, 
fetal bovine serum (FBS) and RPMI-1640 medium were purchased from Invitrogen. 
siRNA for b-cell lymphoma 2 (bcl-2) was acquired from Ambion
®
 (TX, USA). The 
GenElute™ Endotoxin-Free plasmid maxiprep kit was acquired from Sigma-Aldrich 
(MO, USA). The enhanced chemiluminescence western blotting detection kit was 
acquired from Amersham (Amersham, UK). All other reagents used in this work were 
obtained from Sigma-Aldrich (MO, USA). 
2.2 Synthesis and characterization of Au PENPs 
2.2.1 Synthesis of PEI-FI-mPEG conjugate 
According to a previous report,
139
 the PEI-FI conjugate was synthesized with a 
FI:PEI molar ratio of 7:1. FI in 5 mL dimethyl sulfoxide (DMSO) solution (3.27 mg, 
8.40 mmol) was added dropwise into a solution of PEI dissolved in 5 mL DMSO 
(30.00 mg, 1.20 mmol) under vigorous magnetic stirring at room temperature 
overnight. The reaction mixture was dialyzed against phosphate buffered saline (PBS) 
(3 times, 2L) for 1.5 days and distilled water (3 times, 2L) for 1.5 days through a 1000 
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MWCO membrane to remove the excess of reactants. This was followed by 
lyophilization. 
Using the prepared PEI-FI conjugate, PEI-FI-mPEG conjugates were synthesized 
with mPEG:PEI molar ratios of 1:1. The COOH group of mPEG-COOH (2.40 mg, 
1.20 mmol) was first activated with EDC (2.30 mg, 12.00 mmol) and NHS (1.38 mg, 
12.00 mmol) in 3 mL DMSO at room temperature for 3h. The resulting solution of 
activated mPEG-COOH was added dropwise into a solution of PEI-FI dissolved in 5 
mL DMSO under vigorous magnetic stirring at room temperature for 3 days. The 
reaction mixture was dialyzed against PBS (3 times, 2L) for 1.5 days and distilled 
water (3 times, 2L) for 1.5 days through a 10000 MWCO membrane to remove the 
excess of reactants. This was followed by lyophilization. 
2.2.2 Synthesis of PEI-FI-(PEG-FA) conjugate 
The PEG-FA conjugate was synthesized according to a previously reported 
method.
139
 FA (26.48 mg, 60.00 mmol) was ﬁrst activated with EDC (11.50 mg, 60.00 
mmol) and NHS (6.91 mg, 60.00 mmol) in DMSO (4 mL) at room temperature for 3 
h. The resulting solution of activated FA was added dropwise into the 4 mL DMSO 
solution of NH2-PEG-COOH (60.00 mg, 30.00 mmol) under vigorous magnetic 
stirring at room temperature for 1 day. The reaction mixture was dialyzed against PBS 
(3 times, 2 L) for 1.5 days and water (3 times, 2 L) for 1.5 days using a dialysis 
membrane with MWCO of 1000. This was followed by lyophilization. 
PEI-FI-(PEG-FA) conjugates were synthesized taking into account PEG:PEI 
molar ratios of 1:1. For this, PEI-FI conjugates were first prepared following the same 
method described in Section 2.2.1. The COOH group of PEG-FA (5.27 mg, 2.16 
mmol) was first activated with EDC (4.14 mg, 21.60 mmol) and NHS (2.49 mg, 21.60 
mmol) in 5 mL DMSO at room temperature for 3 h. The resulting solution of 
activated COOH-PEG-FA was added dropwise into PEI-FI in 5 mL DMSO solution 
under vigorous magnetic stirring at room temperature for 3 days. The reaction mixture 
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was dialyzed against PBS (3 times, 2L) for 1.5 days and distilled water (3 times, 2L) 
for 1.5 days through a 10000 MWCO membrane to remove the excess of reactants. 
This was followed by lyophilization. 
2.2.3 Entrapment of Au NPs 
Based on a previously reported protocol,
140-141
 the PEI-FI-mPEG and 
PEI-FI-(PEG-FA) conjugates synthesized above were used as templates to entrap Au 
NPs. In each case, molar ratios of 10:1, 25:1 and 50:1 between gold and PEI in each 
respective conjugate were used to prepare the different Au PENPs. In brief, 200 μL of 
48.6 mg/mL HAuCl4 aqueous solution was added to the appropriate amount of 
conjugates in 10 mL distilled water under vigorous magnetic stirring for 30 min at 
room temperature. An icy cold NaBH4 solution (1 mL in water/methanol, v/v = 2:1) 
with 5 molar equivalents of the gold salt was added to the conjugate/gold salt mixture 
under vigorous stirring. The reaction mixture turned to a deep-red color within a few 
seconds after adding the NaBH4 solution and the stirring process was continued for 2 
h to complete the reaction. The reaction mixture was dialyzed against PBS (3 times, 
2L) for 1.5 days and distilled water (3 times, 2L) for 1.5 days through a 10000 
MWCO membrane to remove the excess of reactants. This was followed by 
lyophilization. 
2.2.4 Characterization of Au PENPs 
1
H NMR spectra of all samples (5 mg sample dissolved in 0.55 mL D2O or 
DMSO) were taken at room temperature by using a Bruker 400 MHz Avance II
+
 
NMR spectrometer. The grafting degree of ligand onto the polymer was determined 
from the ratio between the peaks through integration and calculation.  
UV-Vis spectra of all samples with a concentration of 0.15 mg/mL in distilled 
water were performed by using a Lambda 2 UV-Vis spectrometer (Perkin-Elmer, 
USA).  
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The hydrodynamic size and zeta potential of all the samples were measured by a 
Zetasizer Nano-ZS (Malvern). The hydrodynamic size of the particles was determined 
with a scattering angle of 173° at 25 °C. The zeta potential of the particles was 
measured by using a standard capillary electrophoresis cell in the Zetasizer Nano ZS 
with a detection angle of 17° at 25 °C. The measurements were performed in 
triplicates. 
2.3 Preparation and characterization of polyplexes 
2.3.1 Amplification of pDNA 
pDNA encoding for luciferase and enhanced green fluorescent protein 
(pEGFPLuc, 6.4 kb) with a cytomegalovirus promoter was used. Escherichia coli host 
strain DH5α containing the plasmid was grown overnight in Luria-Broth Base medium 
with Kanamycin (50 μg/mL). The pDNA was isolated and purified by using the 
GenElute™ Endotoxin-Free plasmid maxiprep kit. The concentration of pDNA was 
assessed at 260 nm and 280 nm via a GBC Cintra 40 UV-Vis spectrometer. The pDNA 
was stored -20 °C until further use. 
2.3.2 PicoGreen intercalation assay 
Polyplexes using a fixed amount of pDNA (0.2 μg) and different concentrations 
of samples were prepared in a final volume of 100 μL TE buffer (10 mM Tris, 1 mM 
EDTA, pH 7.5) per well of an opaque 96-well plate. After 20 min incubation at room 
temperature, 100 μL of PicoGreen® reagent diluted in TE buffer was added to each 
well and mixed gently. The mixtures were protected from the light and incubated for 5 
min at room temperature. Using a microplate reader (model Victor 1420, 
PerkinElmer), the PicoGreen
®
 fluorescence emission was measured (λex = 485 nm, 
λem = 535 nm). All experiments were performed in triplicate and the relative 
fluorescence percentage (%F) was determined using 
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%F =  
𝐹 𝑐𝑜𝑚𝑝𝑙𝑒𝑥−𝐹 𝑏𝑙𝑎𝑛𝑘
𝐹 𝑓𝑟𝑒𝑒𝐷𝑁𝐴−𝐹 𝑏𝑙𝑎𝑛𝑘
 × 100                                         (1) 
The fluorescent value of free DNA was considered as 100%. 
2.3.3 Hydrodynamic size and zeta potential measurements of 
polyplexes 
The hydrodynamic size and zeta potential of the polyplexes, which were made of 
polymer and pDNA at room temperature, were measured by using a Zetasizer 
Nano-ZS (Malvern). The polyplexes were prepared in water to a final volume of 1 mL, 
where increasing amounts of conjugates were added to a fixed amount pDNA (4 ug). 
The samples were then vortexed for 30 s. After incubation for 10 min at room 
temperature, the measurements were carried out. The measurements were performed 
in triplicate. 
2.4 Gene transfection studies 
2.4.1 Cytotoxicity studies 
The A2780 human ovarian carcinoma cells were grown in RPMI-1640 medium 
supplemented with 10% FBS and 1% Antibiotic and Antimycotic (AbAm) solution in 
a humidified atmosphere at 37 °C and 5% CO2. After a cell confluence of 90% was 
reached, the A2780 cells were subcultured and seeded into 48-well cell culture plates 
at 4.5 × 10
4
 cells/well using 0.5 mL of cell culture medium. The cells were then 
incubated overnight in a humidified atmosphere at 37 °C and 5% CO2. 
One hour prior to performing the cytotoxicity studies, the spent cell culture 
medium was replaced with 0.5 mL fresh serum-free medium per well. During this 
time, the different polyplexes were prepared by adding different concentrations of the 
polymers (0~3000 nM) to a constant amount of pDNA (the equivalent of 2 μg per 
well). The resultant mixtures, which were prepared to a final volume of 100 μL, were 
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vortexed for 30 s and incubated for 10 min at room temperature. Subsequently, the 
prepared samples were added to each respective well. After 24 h, the cytotoxicity of 
the samples on the A2780 human ovarian carcinoma cell line was evaluated. This was 
done by determining the percentage of cell viability using the resazurin reduction 
assay, which establishes a correlation between the number of viable cells in culture 
and the cellular metabolic activity. The diluted resazurin reagent (0.1 mg/mL in RPMI 
medium) was added to every well and the cells were incubated in a humidified 
atmosphere with 37 °C and 5% CO2. After 3 h incubation, 100 μL of the resultant 
medium in each well was transferred to opaque-walled 96-well plates and the 
resorufin fluorescence was measured (λex = 530 nm, λem = 590 nm) using the 
microplate reader. Untreated cells were considered as having 100% cell viability. All 
measurements were taken in triplicate. 
2.4.2 In vitro transfection assay 
The A2780 cells, which were grown overnight in RPMI-1640 medium 
supplemented with 10% FBS and 1% AbAm solution in a humidified atmosphere at 
37 °C and 5% CO2, were subcultured and then seeded into 48-well cell culture plates 
at 4.5 × 10
4
 cells/well using 0.5 mL of cell culture medium. The cells were then 
incubated overnight in a humidified atmosphere at 37 °C and 5% CO2. One hour prior 
to transfection, the cell culture medium was replaced with 0.5 mL fresh serum-free 
medium per well. Polyplexes solutions were prepared during this time by mixing a 
constant amount of pDNA (2 μg pDNA/well) with different vectors at the selected 
N:P ratio for 30 s and then incubating for 10 min at room temperature. Subsequently, 
transfection was carried out by adding 100 μL of the prepared polyplexes solutions to 
the corresponding wells. 
After incubating the cells with the polyplexes for 6h, the cell culture medium 
was replaced with 1 mL serum-containing medium. After further incubation for 48 h, 
transfection was qualitatively assessed by monitoring the expression of the EGFP 
gene using an inverted fluorescene microscope (TE2000-E, Nikon Eclipse). The 
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images of the transfected cells were acquired using the NIS Elements Advanced 
Research software (version 2.31). The medium was then removed entirely from the 
cultured cells. PBS was used to rinse the cells. RLB (100 μL) was dispensed into 
every well and then the plates were placed in the -80 °C refrigerator overnight. 
Following the manufacturer’s instructions, the total protein and luciferase activity in 
the cell lysates were characterized using the bicinchoninic acid (BCA) assay and 
Promega’s luciferase assay, respectively. All samples were run in triplicate. The 
transfection efficiency was determined quantitatively by evaluating the firefly 
luciferase expression and denoted as relative light units per mg of protein (RLU/mg 
protein) ± standard deviation (SD). Non-transfected cells were used as a negative 
control. 
2.4.3 Evaluation of cell-targeting capabilities 
To investigate whether the uptake of the Au PENPs was receptor-mediated, the 
cells were pre-treated with FA to block the FA receptors. This was done by adding 100 
μL FA solution (5 μM in serum-free medium) to the A2780 cells which were seeded in 
48-well plates 24 h prior to starting this experiment. After incubation for 1 h the cells 
were then transfected with the vector/pDNA polyplexes under the same conditions as 
described in Section 2.4.2.  
2.5 Gene silencing 
2.5.1 Agarose gel electrophoresis retardation assay  
Increasing concentrations of polymer and a fixed amount of siRNA (5 pmol) 
were prepared taking into account different nitrogen:phosphate (N:P) ratios (2.5-30), 
which corresponds to the molar ratio of amine groups in the polymer to phosphate 
groups in the siRNA backbone. The mixtures in 6 μL diethylpyrocarbonate 
(DEPC)-treated water were combined by gentle vortexing and were then incubated for 
15 min at room temperature. After incubation, the complexes were analyzed by 
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agarose gel electrophoresis. For this a 1.0 % (w/v) agarose gel containing ethidium 
bromide (0.04 μL/mL) was prepared and the samples were then electrophoresed using 
a current of 120 V for 10 min in TAE buffer solution (40 mM Tris-HCl, 1% v/v acetic 
acid, 1 mM EDTA). After acquiring images of the gels, the retardation band of each 
respective complex was assessed. 
2.5.2 Hydrodynamic size and zeta potential measurement of 
complexes 
The hydrodynamic size and zeta potential of the complexes, which were made of 
polymer and siRNA at room temperature, were measured by using a Zetasizer 
Nano-ZS (Malvern). At first, 900 ng of siRNA was diluted using ultrapure water in 
each microcentrifuge tube. At selected polymer/siRNA ratios, the complexes were 
prepared in a total volume of 1 mL and vortexed for 30 s. After incubation for 10 min 
at room temperature, the measurements were carried out. The measurements were 
performed in triplicate. 
2.5.3 siRNA transfection 
Using RPMI-1640 medium supplemented with 10% FBS and 1% AbAm, A2780 
cells were seeded in 24-well plates at a density of 4 × 10
4
 cells/well. After 24 h, the 
spent culture medium was removed and the cells were washed twice with PBS. The 
Au PENP/siRNA complexes at selected N:P ratios were prepared in DEPC-treated 
water and were added to the cells in 200 μL fresh serum-free medium. Here, a final 
volume of 20 μL of the complexes was added per well (each well contained 1.5 μL 10 
μM siRNA). After incubation for 4 h at 37 °C, the cells were washed with PBS twice. 
RPMI-1640 medium supplemented with 10% FBS and 1% AbAm was added to the 
cells. After 48 h of incubation, the cells were washed with PBS twice. The cells were 
then removed from the well surface and then collected by centrifugation at 800 g for 
10 min at 4 °C. The cells were lysed by 20 μL 1 × RLB and then freeze-thawing 3 
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times. The amount of protein in the cell lysates was quantitated by the BCA assay, 
with bovine serum albumin (BSA) being used as a standard.  
2.5.4 Western blotting 
According to the report,
142
 an equivalent of 2 μg protein was aliquoted into a 
microcentrifuge tube and was mixed with loading buffer, using the cell lysates 
prepared in Section 2.5.3. The prepared mixtures were then heated at 100 °C for 8 min. 
The protein lysates were subsequently assessed by 15% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene 
fluoride blotting membranes. After blocking the membranes with 5% BSA, they were 
incubated with the primary anti bcl-2 antibody (1:200 dilution in blocking medium) 
overnight at 4 °C. The membranes were then washed 3 times with Tris-buffered 
saline/tween-20 (TBST) for 10 min each time. Next, the membranes were incubated 
with horseradish peroxide conjugated secondary antibody (1:1000 dilution in blocking 
medium) for 2 h at room temperature while shaking. After washing 3 times with 
TBST at 10 min intervals, the membranes were incubated with the primary 
anti-tubulin antibody (1:1000 dilution in blocking medium) overnight at 4 °C. The 
membranes were subsequently washed 3 times with TBST for 10 min each time. They 
were then incubated with horseradish peroxide conjugated secondary antibody 
(1:1000 dilution in blocking medium) for 2 h at room temperature while shaking. This 
was followed by washing 3 times with TBST for 10 min each time. Finally, the blots 
were assessed using an Enhanced Chemiluminescence Western Blotting Detection Kit. 
The protein bands were analyzed using the Image-J software. 
In order to determine the gene silencing efficiency of the complexes, the 
expression of the protein of interest (in this case bcl-2) can be normalized relative to 
the expression of the internal protein control (in this case tubulin) within the same 
sample
142
. For this, the normalized intensity of bcl-2 in the sample treated with bcl-2 
siRNA can be compared with the normalized intensity of bcl-2 in the sample that 
underwent no bcl-2 siRNA treatment (see Equation 2). The percentage calculated 
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using this information corresponds to the expression of the remaining bcl-2 protein in 
the sample after transfection with the complexes. 
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑏𝑐𝑙­2 (𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑏𝑐𝑙­2 𝑠𝑖𝑅𝑁𝐴) 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑇𝑢𝑏𝑢𝑙𝑖𝑛 (𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑏𝑐𝑙­2 𝑠𝑖𝑅𝑁𝐴)⁄
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑏𝑐𝑙­2 (𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑏𝑐𝑙­2 𝑠𝑖𝑅𝑁𝐴) 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑇𝑢𝑏𝑢𝑙𝑖𝑛 (𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑏𝑐𝑙­2 𝑠𝑖𝑅𝑁𝐴)⁄
× 100% (2) 
2.6 Statistics 
One-way ANOVA statistical analyses with Tukey’s test were carried out to assess 
the statistical significance of the experimental data. All results are reported as mean ± 
SD. 0.05 was selected as the significance level and the data was indicated with (*) for 
p < 0.05, (**) for p < 0.01 and (***) for p <0.001, respectively.  
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CHAPTER 3 – RESULTS AND DISCUSSION 
3.1 Preparation of Au PENPs 
3.1.1 Synthesis and characterization of PEI-FI-mPEG conjugate 
In this work, a novel non-viral vector for nucleic acid delivery was prepared. PEI, 
which is amongst the typically used polymeric gene vectors,
143
 was selected as the 
polymer backbone in this study, as it possesses a large number of amine groups that 
are able to condense nucleic acid, buffer and rupture the acidic environment of 
endolysosomes, resulting in the superior transfection efficiency.
144
 The FI moiety, 
which is generally used as a fluorescent probe, was covalently conjugated onto the 
PEI backbone in order to trace the intracellular uptake of PEI. The mPEG moiety was 
further coupled to the PEI backbone by covalent attachment so as to increase the 
hydrophilicity and reduce the cytotoxicity of the prepared conjugate. 
The first step in the overall synthesis of the PEI-FI-mPEG conjugate involved the 
preparation of the PEI-FI conjugate using PEI and FI (see synthesis process depicted 
in Figure 7). The 
1
H NMR spectra of PEI and FI are shown in Figure 33 and Figure 
34 respectively in ANNEX I. In the 
1
H NMR spectrum acquired for the PEI-FI 
conjugate in D2O (Figure 8), the chemical shift between 2.0 and 3.4 ppm was 
assigned to the characteristic proton peaks of PEI containing eight broad, overlapping 
peaks, while the chemical shift between 6.5 and 8.0 ppm was assigned to the 
characteristic proton peaks of the FI moiety.
144-146
 Because free FI moieties were 
cleared out from the reaction mixture during dialysis, the FI peaks in the 
1
H NMR 
spectrum of PEI-FI may be attributed to the FI moieties that were covalently attached 
to the PEI backbone. Based on the integration of the relevant peaks, the ratio of FI 
moieties attached onto the PEI backbone was estimated to be 6: 1. 
In the second step, the PEI-FI-mPEG conjugate was synthesized through 
conjugation of mPEG to the above prepared PEI-FI conjugate. The 
1
H NMR spectrum  
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Figure 8 
1
H NMR spectrum of PEI-FI in D2O. The chemical shift at 4.79 ppm corresponds to the D2O 
solvent. The letters in the PEI-FI conjugate structure correspond to the peaks identified in 
1
H NMR 
spectrum. 
of mPEG is presented in ANNEX I (Figure 35). In the 
1
H NMR spectrum of 
PEI-FI-mPEG in D2O shown in Figure 9, the characteristic peak of the mPEG 
methylene protons can be seen at 3.7 ppm. This chemical shift represents only the 
mPEG moieties that were covalently attached to PEI-FI, since any free mPEG 
moieties were cleared out from the reaction mixture during dialysis. Based on the 
integration of the relevant peaks, the ratio of PEI: FI: mPEG was estimated to be 
1:6:1. 
UV-Vis spectroscopy was used for further characterization of the synthesized 
conjugates. From the UV-Vis spectra acquired for PEI-FI and PEI-FI-mPEG (Figure 
10), absorbance peak at 495 nm is evident, which corresponds to the characteristic 
absorption of FI.
147
 This data combined with the NMR analysis above, indicated the 
successful synthesis of the PEI-FI-mPEG conjugate. 
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Figure 9 
1
H NMR spectrum of PEI-FI-mPEG in D2O. The chemical shift at 4.79 ppm corresponds to 
the D2O solvent. The letters in the PEI-FI-mPEG conjugate structure correspond to the peaks identified 
in 
1
H NMR spectrum. 
 
Figure 10 UV-Vis spectra of the PEI-FI (a) and the PEI-FI-mPEG (b) conjugates. Each sample was 
prepared in distilled water at a concentration of 0.15 mg/mL. 
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3.1.2 Synthesis and characterization of PEI-FI-(PEG-FA) conjugate 
For the purpose of targeted gene therapy applications, PEI-FI-(PEG-FA) 
conjugates were also prepared. In addition to PEI and FI, the properties of which were 
described in Section 3.1.1, FA targeting moieties were conjugated onto the PEI 
polymer. The FA moiety was used as the targeting motif to target nucleic acid delivery 
to cancer cells overexpressing FA receptors, which are receptors known to be 
expressed in most human carcinoma cell lines.
148
 The PEG moiety, which served as a 
spacer, was covalently linked between PEI and FA. This was done not only to 
decrease the hydrophobicity and cytotoxicity of the conjugate, but also to increase the 
targeting probability of FA in each of the prepared conjugate systems. 
For the synthesis of the PEI-FI-(PEG-FA) conjugate, the PEG-FA was first 
prepared. This was achieved through conjugation of activated FA onto the terminal 
amine group of PEG (see synthesis process depicted in Figure 11). The 
1
H NMR 
spectra of PEG and FA are shown in Figure 36 and Figure 37 respectively in ANNEX 
I. In the 
1
H NMR spectrum acquired for PEG-FA in D2O (Figure 12), the 
characteristic proton peak at 3.7 ppm was assigned to the PEG moiety, while the 
characteristic proton peaks at 2.0, 6.8, 7.7 and 8.8 ppm were assigned to the attached 
FA moiety.
35
 Because free FA moieties were cleared out from the reaction mixture 
during dialysis, the presence of the characteristic FA and PEG peaks in the 
1
H NMR 
spectrum are indicative of the effective covalent attachment of FA to PEG. Based on 
the integration of the relevant peaks, the ratio of PEG:FA was estimated to be 1:1. 
 
Figure 11 Synthesis process of the PEG-FA conjugate. 
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Figure 12 
1
H NMR spectrum of PEG-FA in D2O. The chemical shift at 4.79 ppm corresponds to the 
D2O solvent. The letters in the PEG-FA conjugate structure correspond to the peaks identified in 
1
H 
NMR spectrum. 
In the next step, the synthesis of the final PEI-FI-(PEG-FA) conjugate involved 
conjugation of PEG-FA onto the terminal amine group of PEI-FI. Figure 13 showed 
the 
1
H NMR spectrum and peak assignment of the final PEI-FI-(PEG-FA) conjugate 
in D2O. The characteristic proton peaks at 2.0-3.4, 6.5, 6.6, 7.1 and 7.3 ppm were 
assigned to the PEI-FI moiety, while the characteristic proton peaks at 1.9, 3.7, 6.9, 
7.7 and 8.7 ppm were assigned to the PEG-FA moiety. Combined, the presence of 
these peaks was indicative of the successful synthesis of PEI-FI-(PEG-FA). 
Furthermore, based on the identification of the characteristic peaks in the conjugate 
and the integration of the relevant peaks, the ratio of PEI:FI:PEG:FA was estimated to 
be 1:7:1:1. 
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Figure 13 
1
H NMR spectrum of PEI-FI-(PEG-FA) in D2O. The chemical shift at 4.79 ppm corresponds 
to the D2O solvent. The letters in the PEI-FI-(PEG-FA) conjugate structure correspond to the peaks 
identified in 
1
H NMR spectrum. 
 
UV-Vis spectroscopy was further used to characterize the synthesized 
PEI-FI-(PEG-FA) conjugate (Figure 14). For comparison purposes, the UV-Vis 
spectra of PEI-FI and PEG-FA were also included. Both PEI-FI and PEI-FI-(PEG-FA) 
were observed to display an absorbance peak at 495 nm, which corresponds to the 
characteristic absorption of FI.
147
 Relative to PEI-FI, the conjugates possessing FA 
showed absorbance peaks at 280 nm and 360 nm, which correspond to the 
characteristic absorption of FA.
149-150
 Combined, the UV-Vis and NMR data indicated 
the successful synthesis of the PEI-FI-(PEG-FA) conjugate. 
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Figure 14 UV-Vis spectra of the PEI-FI (a), PEG-FA (b) and PEI-FI-(PEG-FA) (c) conjugates. 
Each sample was prepared in distilled water at a concentration of 0.15 mg/mL. 
3.1.3 Preparation and characterization of Au PENPs 
Currently, Au NPs form the focus of nucleic acid delivery studies owing to their 
stability and affinity for nucleic acid. By optimizing several factors, such as size, 
surface coatings and surface charge, Au NPs have been used for enhancing 
transfection efficiency and reducing cytotoxicity.
151
 In this work, the synthesized 
PEI-FI-mPEG and PEI-FI-(PEG-FA) conjugates served as templates to entrap Au NPs 
(see Figure 15). Au atom:PEI molar ratios of 10:1, 25:1 and 50:1 were used to prepare 
the different Au PENPs. 
When in solution, the produced Au PENPs did not aggregate. Relative to the 
respective PEI-FI-mPEG and PEI-FI-(PEG-FA) conjugates, the corresponding Au 
PENPs were also observed to be red in color (see Figure 16) thereby providing 
evidence for the formation of Au PENPs. Furthermore, this red color was observed to 
become more prominent with an increase in the molar ratio of Au atom:PEI from 10:1 
to 50:1. 
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Figure 15 Schematic illustration of the structure of the synthesized Au PENPs prepared using 
PEI-FI-mPEG (a) and PEI-FI-(PEG-FA) (b). 
 
 
Figure 16 Photographs of PEI-FI-mPEG (a), (Au
0
)50-PEI-FI-mPEG (b), (Au
0
)25-PEI-FI-mPEG (c), 
(Au
0
)10-PEI-FI-mPEG (d), PEI-FI-(PEG-FA) (e), (Au
0
)50-PEI-FI-(PEG-FA) (f), 
(Au
0
)25-PEI-FI-(PEG-FA) (g) and (Au
0
)10-PEI-FI-(PEG-FA) (h) dispersed in ultrapure water. The 
concentration of each sample was 1 mg/mL. 
 
UV-Vis spectroscopy was used to characterize the Au PENPs that were 
synthesized. The spectra for the Au PENPs produced using either the PEI-FI-mPEG or 
the PEI-FI-(PEG-FA) conjugates as templates are shown in Figure 17 and Figure 18, 
respectively. For all the Au PENPs, an absorbance peak at 495 nm was apparent in the 
spectrum indicating the characteristic absorption of FI. In the case of all the  
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Figure 17 UV-Vis spectra of PEI-FI-mPEG (a), (Au
0
)10-PEI-FI-mPEG (b), (Au
0
)25-PEI-FI-mPEG 
(c) and (Au
0
)50-PEI-FI-mPEG (d). Each sample was prepared in distilled water at a concentration 
of 0.15 mg/mL. 
 
 
Figure 18 UV-Vis spectra of PEI-FI-(PEG-FA) (a), (Au
0
)10-PEI-FI-(PEG-FA) (b), 
(Au
0
)25-PEI-FI-(PEG-FA) (c) and (Au
0
)50-PEI-FI-(PEG-FA) (d). Each sample was prepared in 
distilled water at a concentration of 0.15 mg/mL. 
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FA-containing Au PENPs (see Figure 18), the presence of FA was confirmed due to 
the presence of the absorbance peaks at 280 nm and 360 nm which correspond to the 
characteristic absorption of FA.
149-150
 The existence of Au NPs in the different Au 
PENPs however was difficult to confirm through UV-Vis as the absorption of the FI 
moieties overlapped the surface plasmon resonance peak of the Au NPs at 520 nm. 
This effect was enhanced when the amount of Au NPs entrapped within the different 
conjugates was extremely low. However, the broad shoulder evident at 550 nm in the 
spectra acquired for each Au NP-containing sample provides an indication of the 
existence of the Au NPs.
152
 This shoulder was observed to become more prominent as 
the molar ratio of Au atom:PEI increased. In contrast, samples without Au NPs don’t 
show this specific absorbance feature. 
3.2 Characterization of polyplexes formed by conjugates and 
Au PENPs with pDNA 
3.2.1 PicoGreen intercalation assay 
In order to ensure cell entry, compaction of pDNA by the vector is crucial. Thus, 
to assess the pDNA compaction capabilities of the different vectors that were 
synthesized, the PicoGreen
®
 intercalation assay was used. PicoGreen
®
, which is a 
high affinity intercalator, is practically non-fluorescent in its free form and becomes 
highly fluorescent after binding free double stranded DNA.
153
 
Figure 19 shows the PicoGreen
®
 intercalation assay data obtained for each 
pDNA/conjugate and pDNA/Au PENP polyplexes. The fluorescent signal acquired 
for free pDNA (N:P ratio of 0) indicates that PicoGreen
®
 is completely bound to it. 
The relative fluorescence intensity recorded for each pDNA/conjugate and pDNA/Au 
PENP polyplexes was then observed to decrease with an increase in the concentration 
of the vector under investigation (i.e., with increasing N:P ratios), thereby indicating 
the ability of each vector to compact pDNA. Moreover, complete pDNA packaging  
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Figure 19 PicoGreen
®
 intercalation assay of pDNA bound to either PEI (a), PEI-FI-mPEG (b), 
(Au
0
)10-PEI-FI-mPEG (c), (Au
0
)25-PEI-FI-mPEG (d), (Au
0
)50-PEI-FI-mPEG (e), PEI-FI-(PEG-FA) (f), 
(Au
0
)10-PEI-FI-(PEG-FA) (g), (Au
0
)25-PEI-FI-(PEG-FA) (h) or (Au
0
)50-PEI-FI-(PEG-FA) (i). N:P ratios 
ranging from 0 (pDNA only) to 10 were assessed. The results are reported as the relative percentage of 
PicoGreen fluorescence, in which 100% intensity corresponds to zero concentration of polyplexes 
(only pDNA). All results were expressed as the mean ± SD, n = 3. 
was achieved by each vector when using a N:P ratio of 2.5 or more, relealing that 
pDNA is no longer accessible to this intercalating fluorochromes.
29, 154-156
 Thus N:P 
ratos of 5 were selected to further study. 
3.2.2 Hydrodynamic size and zeta potential measurements 
The hydrodynamic size and zeta potential of pDNA/vector ployplexes are known 
to be critical factors that influence gene delivery. For this purpose, DLS and zeta 
potential measurements can be acquired to evaluate the size and zeta potential of any 
polyplexes of interest. 
Figure 20 (also see ANNEX I, Table 1) shows the hydrodynamic size of the 
different pDNA/vector polyplexes that were prepared using the selected N:P ratio. 
The polyplexes formed between pDNA with vectors based on PEI-FI-mPEG showed a 
relatively larger hydrodynamic radius (203~360 nm), while the polyplexes formed 
between pDNA with vectors based on PEI-FI-(PEG-FA) showed a relatively smaller 
hydrodynamic radius(138~171 nm), which is presumably due to the influence of the  
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Figure 20 Hydrodynamic size of the polyplexes prepared by complexing pDNA with PEI (1), 
PEI-FI-mPEG (2), (Au
0
)10-PEI-FI-mPEG (3), (Au
0
)25-PEI-FI-mPEG (4), (Au
0
)50-PEI-FI-mPEG (5), 
PEI-FI-(PEG-FA) (6), (Au
0
)10-PEI-FI-(PEG-FA) (7), (Au
0
)25-PEI-FI-(PEG-FA) (8) and 
(Au
0
)50-PEI-FI-(PEG-FA) (9). All results were expressed as the mean ± SD, n =3. 
FA structure or property. These polyplexes were in nano-scale, which indicated that 
there was no aggregate in solution. The hydrodynamic radius of them were similar 
with that of pDNA/PEI polyplexes, so they might be uptaken by cells. There is the no 
significant difference between groups (ANNEX I, Table 1). 
The zeta potentials of the different pDNA/vector polyplexes, which were 
prepared using the selected N:P ratio, are shown in Figure 21 (also see ANNEX I, 
Table 1). For all the polyplexes of the synthesized vectors, positive zeta potential 
values of 40~45 mV were recorded. Since these polyplexes were positively charged, 
they were likely to establish electrostatic interactions with the negatively charged cell 
membrane thereby promoting pDNA delivery. Furthermore, the steric shielding effect 
of PEGylation, which is that the zeta potential decreased with the number of the PEG 
moieties grafted at the conjugate surface, was one of the most important approaches to 
control surface charge.
80, 157
 But in this case, since the number of the PEG moieties 
attached was less, the zeta potential values acquired for the different polyplexes did 
not indicate the steric shielding effect of PEGylation, but showed the reverse 
phenomenon with no significance difference (as can be seen by the zeta potential 
values recorded in Table 1 in ANNEX I).  
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Figure 21 Zeta potential of the polyplexes prepared by complexing pDNA with PEI (1), PEI-FI-mPEG 
(2), (Au
0
)10-PEI-FI-mPEG (3), (Au
0
)25-PEI-FI-mPEG (4), (Au
0
)50-PEI-FI-mPEG (5), PEI-FI-(PEG-FA) 
(6), (Au
0
)10-PEI-FI-(PEG-FA) (7), (Au
0
)25-PEI-FI-(PEG-FA) (8) and (Au
0
)50-PEI-FI-(PEG-FA) (9). All 
results were expressed as the mean ± SD, n =3. 
3.3 Gene delivery 
3.3.1 Cytotoxicity studies 
Prior to assessing the nucleic acid delivery applications of the synthesized 
vectors, their cytotoxicity on A2780 human ovarian carcinoma cells was tested using 
the resazurin cell viability assay (see Figure 22 and Figure 23). Broadly speaking, the 
viability was observed to decrease, when treating the cells with increasing 
concentrations of each vector. Compared to PEI, all the vectors were less toxic 
particularly when using concentrations of 200 nM or higher. Moreover, the cell 
viability was noticeably higher upon treatment with 500 and 1000 nM concentrations 
of the PEG-containing vectors relative to treatment with the equivalent concentrations 
of PEI (p<0.001). This may be due to the fact that PEG surface modification of the 
PEI backbone increases the hydrophilicity of the polyplexes, which alleviates the 
strong electrostatic interaction between the vector and the cell surface, consequently 
resulting in a reduced cytotoxic effect.
158
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Figure 22 Resazurin cell viability assay on A2780 human ovarian carcinoma cells after treatment with 
PEI (a), PEI-FI-mPEG (b), (Au
0
)10-PEI-FI-mPEG (c), (Au
0
)25-PEI-FI-mPEG (d) and 
(Au
0
)50-PEI-FI-mPEG (e). In each case increasing concentrations of each vector were used to treat the 
cells. All results were expressed as the mean ± SD, n =3. 
 
 
Figure 23 Resazurin cell viability assay on A2780 human ovarian carcinoma cells after treatment with 
PEI (a), PEI-FI-(PEI-FA) (b), (Au
0
)10-PEI-FI-(PEI-FA) (c), (Au
0
)25-PEI-FI-(PEI-FA) (d) and 
(Au
0
)50-PEI-FI-(PEI-FA) (e). In each case increasing concentrations of each vector were used to treat 
the cells. All results were expressed as the mean ± SD, n =3. 
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Further comparison of the Au NP-free and Au NP-containing conjugate systems 
(see Figure 22 and Figure 23) also revealed a difference in cytotoxic effects. Overall, 
cell viability was notably increased for the cells undergoing treatment with the Au 
NPs-containing conjugate systems relative to their Au-free counterparts. Thus, 
entrapment of Au NPs seems to be good for reducing cytotoxicity. This may be 
explained by the fact that the amine group of PEI, which contributes to the cytotoxic 
effects of the polymer, behave as reductant and stabilizer, as well as bind colloidal 
Au tightly via the available electron lone pairs.
159-161
 This entrapment of the Au NPs 
leads to a decrease in the number of free amines, resulting in lower cytotoxicity. 
3.3.2 In vitro transfection assay 
The gene transfection efficiency of the Au PENP/pDNA polyplexes was 
investigated through the delivery of pEGFPLuc into A2780 human ovarian carcinoma 
cells in vitro. For this, pEGFPLuc expression was assessed 48 h post-transfection by 
monitoring the fluorescent and luminescent properties of EGFP and Luc, respectively. 
In the first set of the gene delivery studies, the cells were assayed for expression 
of the Luc reporter gene. The luciferase activity, which was normalized for the protein 
content, is shown as RLU in Figure 24. Compared to PEI, the PEI-FI-mPEG 
conjugate demonstrated an enhanced transfection efficiency. In contrast, relative to 
PEI-FI-mPEG, a reduction in transfection efficiency was observed when using the 
corresponding Au PENP vectors (p<0.01).Compared to PEI, the PEI-FI-(PEG-FA) 
and the corresponding Au PENP vectors demonstrated an reduced transfection 
efficiency without the significant difference. 
The gene delivery ability of the different vector systems was then qualitatively 
evaluated by visualization of EGF expression using fluorescence microscopy. Figure 
25 shows the fluorescence microscopy images that were acquired. As can be seen by 
the expression of EGFP in the fluorescence microscopy images, all the synthesized 
conjugates and Au PENPs were able to successfully transfect the A2780 cells. 
Moreover, the transfection efficiency observed for each vector was in accordance with 
the observations recorded through quantitative analysis of the Luc reporter gene. 
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Figure 24 In vitro Luc gene expression in A2780 human ovarian carcinoma 48 h post-transfection. 
Cells were treated with polyplexes prepared using pDNA complexed with PEI (1), PEI-FI-mPEG (2), 
(Au
0
)10-PEI-FI-mPEG (3), (Au
0
)25-PEI-FI-mPEG (4), (Au
0
)50-PEI-FI-mPEG (5), PEI-FI-(PEG-FA) (6), 
(Au
0
)10-PEI-FI-(PEG-FA) (7), (Au
0
)25-PEI-FI-(PEG-FA) (8) ,(Au
0
)50-PEI-FI-(PEG-FA) (9). All results 
were expressed as the mean ± SD, n = 3. 
 
Combined, this data indicates that the positively charged polyplexes, in which 
the negatively charged nucleic acid was neutralized by the synthesized vector (see 
Section 3.2.2), interacted with the negatively charged cell membrane and was 
internalized into the cell. Overall, the efficiency of cell transfection was dependent on 
the charge properties of the vector used. The more positively charged the vector 
making up the polyplexes, the better the transfection efficiency. In the case of the Au 
PENPs, the molar ratio of Au atom:PEI was found to influence transfection efficiency, 
with the Au atom:PEI molar ratio of 50:1 demonstrating the best results. This may be 
due to the reduction of interior space in the polymer and the decrease in the number of 
amines in the conjugates after entrapment of the Au NPs. Finally, the noticeable 
difference in transfection efficiency between the PEI-FI-mPEG and the 
PEI-FI-(PEG-FA) based vector systems may be attributed to the FA moiety. The 
presence of this moiety in the vector system may have an influence on the structure of 
the conjugate, resulting in lower transfection efficiency. 
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Figure 25 EGFP expression in A2780 human ovarian carcinoma 48 h post-transfection. Cells were 
treated with polyplexes prepared using pDNA complexed with PEI (A-C), PEI-FI-mPEG (a-c), 
(Au
0
)10-PEI-FI-mPEG (d-f), (Au
0
)25-PEI-FI-mPEG (g-i), (Au
0
)50-PEI-FI-mPEG (j-l), PEI-FI-(PEG-FA) 
(m-o), (Au
0
)10-PEI-FI-(PEG-FA) (p-r), (Au
0
)25-PEI-FI-(PEG-FA) (s-u) ,(Au
0
)50-PEI-FI-(PEG-FA) (y-x). 
Bright field images (first and fourth row), fluorescence microscopy images (second and fifth row) and 
the corresponding merged micrographs (third and sixth row) are shown. 
 
3.3.3 Evaluation of cell-targeting capabilities 
To achieve targeted gene delivery to cancer cells overexpressing FA receptors on 
their membrane surface, the FA moiety was selected as the targeting ligand to be 
conjugated onto PEI. Thus, the high affinity of FA receptors for FA is expected to play 
a role in specifically binding and internalizing the PEI-FI-(PEG-FA) conjugate and its 
respective Au PENPs. In order to evaluate this and determine whether the uptake of 
these vectors is receptor-mediated, gene transfection studies using A2780 human 
ovarian carcinoma cells that overexpress the FA receptor were performed. Here, the 
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cells were first pre-treated with FA for 1 h to block the FA receptors and then 
transfected with the different pEGFPLuc/vector polyplexes. The pEGFPLuc 
expression was finally assessed 48 h post-transfection by monitoring the fluorescent 
and luminescent properties of EGFP and Luc, respectively. 
The gene transfection efficiency of PEI-FI-(PEG-FA) and its respective Au 
PENPs as analyzed by luciferase activity and EGFP expression using fluorescence 
microscopy are illustrated in Figure 26 and Figure 27, respectively. Taken as a whole, 
the same trend in cell-targeting capabilities was detected. For each vector/pDNA 
polyplexes, the degree of internalization into the A2780 cells was poor with or 
without FA-receptor blocking as can be seen by the low expression of Luc (Figure 26) 
and EGFP (Figure 27). Clearly, the cell-targeting capability of each FA-containing 
vector was not as expected. This is likely to be a result of the molar ratio of FA to PEI 
in the system being low. 
 
Figure 26 In vitro Luc gene expression in A2780 human ovarian carcinoma cells 48 h post-transfection. 
Cells were pre-incubated with FA 1 h prior to treatment with the polyplexes that were prepared by 
mixing pDNA with PEI-FI-(PEG-FA) (1), (Au
0
)10-PEI-FI-(PEG-FA) (2), (Au
0
)25-PEI-FI-(PEG-FA) (3) 
and (Au
0
)50-PEI-FI-(PEG-FA) (4). The cells were pre-treated without (a) and with (b) FA, respectively. 
All results were expressed as the mean ± SD, n =3. 
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Figure 27 EGFP expression in A2780 human ovarian carcinoma cells 48 h post-transfection. Cells were 
pre-incubated with FA 1 h prior to treatment with the polyplexes that were prepared by mixing pDNA 
with PEI-FI-(PEG-FA) (a-c), (Au
0
)10-PEI-FI-(PEG-FA) (d-f), (Au
0
)25-PEI-FI-(PEG-FA) (g-i) and 
(Au
0
)50-PEI-FI-(PEG-FA) (j-l). Bright field images (first row), fluorescence microscopy images 
(second row) and the corresponding merged micrographs (third row) are shown. 
Thus, it is possible that during the transfection process adsorptive endocytosis induced 
by the positively charged PEI is more prominent than receptor-mediated endocytosis 
induced by the FA moiety. 
3.4 Gene silencing 
3.4.1 Agarose gel electrophoresis retardation assay 
Based on the gene delivery study above, for the PEI-FI-(PEG-FA) based Au 
PENPs, higher transfection efficiency occurred at Au atom:PEI ratio of 50:1, while 
higher transfection efficiency occurred at Au atom:PEI ratio of both 50:1 and 25:1 for 
the PEI-FI-mPEG based Au PENPs. Moreover, the cell viability at Au atom:PEI ratio 
of 50:1 was noticeably higher than that at Au atom:PEI ratio of 25:1 for the 
PEI-FI-(PEG-FA) based Au PENPs and the PEI-FI-mPEG based Au PENPs. So Au 
PENPs at Au atom:PEI ratio of 50:1 were selected for further study.  
For cell entry to occur, compaction of siRNA by the vector system of interest is 
also necessary. In this experiment, the agarose gel retardation assay was used to 
evaluate the ability of the different vector systems that were synthesized to compact 
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siRNA. The principal here lies in the fact that negatively charged siRNA will migrate 
across the agarose gel. Upon complexation with a cationic vector via electrostatic 
interactions, retardation of the siRNA/vector complexes in the gel will be observed 
indicating the neutralization of the siRNA. 
As shown in all the assays in Figure 28, a distinct band was evident at a N:P ratio 
of 0 indicating the migration of the negatively charged siRNA across the gel. With an 
increase in N:P ratio, differences in the migration of the siRNA was detected. This 
observation, which was evidenced in the gels by the siRNA band becoming less 
brilliant and eventually disappearing, was detected for all the complexes that were 
prepared using the vectors under investigation. For the complexes prepared using 
 
Figure 28 Gel retardation assay of siRNA complexed with PEI (a), PEI-FI-mPEG (b), 
(Au
0
)50-PEI-FI-mPEG (c), PEI-FI-(PEG-FA) (d), (Au
0
)50-PEI-FI-(PEG-FA) (e). For each agarose gel, 
N:P ratios of 0 (lane 1), 2.5 (lane 2), 5 (lane 3), 10 (lane 4), 15 (lane 5), 20 (lane 6), 25 (lane 7) and 30 
(lane 8) were prepared. 
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PEI-FI-mPEG and (Au
0
)50-PEI-FI-mPEG, the binding and charge neutralization of 
siRNA occurred at a N:P ratio of 15, while the N:P ratio of 25 were selected for the 
complexes prepared using PEI-FI-(PEG-FA) and (Au
0
)50-PEI-FI-(PEG-FA). 
Compared to the compaction ability of the synthezied vectors, that of PEI were 
relatively higher and occurred at a N:P ratio of 10. Thus N:P ratios of 20 were selected 
for further study. 
3.4.2 Hydrodynamic size and zeta potential measurements 
The hydrodynamic size and zeta potential of siRNA-carrying vectors are also 
considered to be critical factors that will influence gene silencing. To this end, the 
DLS and zeta potential properties of such complexes can be measured in order to 
acquire insights into their size and zeta potential. 
The hydrodynamic size of the complexes formed between siRNA with either PEI, 
PEI-FI-mPEG, (Au
0
)50-PEI-FI-mPEG, PEI-FI-(PEG-FA) or (Au
0
)50-PEI-FI-(PEG-FA) 
using the selected N:P ratios are indicated in Figure 29 (also see ANNEX I, Table 2). 
When compared with siRNA/PEI, the complexes formed between siRNA with 
PEI-FI-mPEG, (Au
0
)50-PEI-FI-mPEG and PEI-FI-(PEG-FA) were larger, while that of 
siRNA complexed with (Au
0
)50-PEI-FI-(PEG-FA) was smaller, which is presumably 
due to the influence of the FA structure or property and the entrapment of Au NPs. 
These complexes were in the nano-scale, which indicated that there was no aggregate 
in solution. The hydrodynamic radius of each sample was similar with that of 
siRNA/PEI complexes, so they might be uptaken by cells. 
In terms of their zeta potential properties, the complexes formed between each 
vector under investigation with siRNA were observed to have an overall positive net 
charge around 23 mV (see Figure 30 and Table 2 in ANNEX I). As a result of this 
positive charge, each siRNA/vector complex is likely to establish electrostatic 
interactions with the negatively charged cell membrane, and cross it as well as 
subsequently introduce the negatively charged siRNA into the cell. 
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Figure 29 Hydrodynamic size of the complexes prepared by complexing siRNA with PEI (1), 
PEI-FI-mPEG (2), (Au
0
)50-PEI-FI-mPEG (3), PEI-FI-(PEG-FA) (4) and (Au
0
)50-PEI-FI-(PEG-FA) (5). 
All results were expressed as the mean ± SD, n = 3. 
 
Figure 30 Zeta potential of the complexes prepared by complexing siRNA with PEI (1), PEI-FI-mPEG 
(2), (Au
0
)50-PEI-FI-mPEG (3), PEI-FI-(PEG-FA) (4) and (Au
0
)50-PEI-FI-(PEG-FA) (5). All results were 
expressed as the mean ± SD, n = 3. 
3.4.3 Western blotting 
Bcl-2, an endogenous regulator of apoptosis, was the first member of the bcl-2 
family to be identified to play a role in inhibiting cell death under different stressful 
conditions.
162
 The siRNA against bcl-2 mRNA can effectively induce apoptosis of 
lymphoma and leukemia cells through the mitochondria-mediated apoptosis 
pathway.
163-164
 Furthermore, the expression of the bcl-2 protein has been observed in 
most of human cancer cell lines.
163
 Therefore, the transfection of siRNA against bcl-2 
may provide an efficacious approach to treat human cancer cells that express bcl-2. 
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Although gene silencing via RNAi technologies are considered as an important 
tool for therapeutic applications, the effective delivery of siRNA into cells stills 
presents a major challenge of gene silencing. In recent years, PEI-based materials 
have attracted considerable attention, owing to the ability of PEI to transport cargo 
molecules across the cell membrane and to promote endosomal escape. As such, this 
experiment focused on investigating the role of PEI-FI-mPEG, PEI-FI-(PEG-FA) and 
the respective Au PENPs in promoting gene silencing. For this, a simple and efficient 
method based on the western blotting techniques was used to assess the silencing of 
the bcl-2 siRNA through analysis of the expression of the corresponding bcl-2 protein. 
The tubulin protein, which was within each sample, served as an internal control. 
Figure 31 shows the western blotting of bcl-2 and tubulin expression in the 
A2780 cells after treatment with the different complexes. For each of the vectors used, 
a clear difference in the expression of the bcl-2 and tubulin proteins was evident. For 
the primary anti-tubulin antibody that was used, the same intense bands corresponding 
to the 50 kDa tubulin protein were seen in the blotting for each of the prepared 
complexes, indicating that the tubulin protein was not silenced. For the 28 kDa bcl-2 
protein on the other hand, the remarkable difference between noticeably less intense 
bands were evident for each complex thereby indicating that silencing of the bcl-2 
gene occurred. 
 
Figure 31 Western blotting evaluation of bcl-2 and tubulin expression in A2780 human ovarian 
carcinoma cells 48 h post-transfection. Cells were treated with complexes prepared using bcl-2 siRNA 
complexed with PEI (lane 1), PEI-FI-mPEG (lane 2), (Au
0
)50-PEI-FI-mPEG (lane 3), PEI-FI-(PEG-FA) 
(lane 4), (Au
0
)50-PEI-FI-(PEG-FA) (lane 5) and were not treated (lane 6). Lane M represented the 
marker. Tubulin served as an internal control for all the samples. 
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The data acquired is shown in the bar chart in Figure 32. Relative to PEI, clear 
differences in the gene silencing efficiency of the vectors was detected. The 
conjugation of PEG onto the PEI backbone decreased the gene silencing efficiency of 
the vectors (p<0.01), while the entrapment of Au NPs in the conjugates contributed to 
an increase in the gene silencing efficiency (p<0.01). It is likely that the entrapment of 
Au NPs in the PEI-FI-mPEG and PEI-FI-(PEG-FA) conjugates results in an increase 
in the accessible surface with which the siRNA can interact. Moreover, as siRNA is 
smaller than pDNA, siRNA can enter the remaining internal room within the Au 
PENPs, thereby interacting more readily with the vectors. In brief, the entrapment of 
Au NPs within the vector systems of interest seems to be a good idea for the gene 
silencing. 
 
Figure 32 Western blotting analysis of gene silencing efficiency in A2780 human ovarian carcinoma 
cells 48 h post-transfection. Cells were treated with complexes prepared using bcl-2 siRNA complexed 
with PEI (1), PEI-FI-mPEG (2), (Au
0
)50-PEI-FI-mPEG (3), PEI-FI-(PEG-FA) (4) and 
(Au
0
)50-PEI-FI-(PEG-FA) (5). 
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CHAPTER 4 – GENERAL CONCLUSION 
 
In this study, a novel non-viral nucleic acid vector system was developed for 
enhanced and targeted nucleic acid delivery applications. In summary, PEI-FI-mPEG 
and PEI-FI-(PEG-FA) conjugates were successfully synthesized and subsequently 
used as templates to entrap Au NPs. The formed conjugates as well as their respective 
Au PENPs, were stable and were thus evaluated as vectors for the delivery of 
different nucleic acid types into A2780 human ovarian carcinoma cells. In the gene 
delivery studies, the PEI-FI-mPEG conjugate displayed relatively high transfection 
efficiency compared to PEI while the transfection efficiency of all the Au PENPs was 
lower. It is likely that the number of free amines and the interior room within the 
conjugates was decreased after Au NP entrapment. Moreover, the obvious rule of FA 
blocking was not shown during the transfection process, probably because the effect 
of electrostatic interactions was more prominent than the targeting effect. Finally, in 
the gene silencing studies, the results indicated that the synthesized Au PENPs with 
the PEGylated FA modification were good non-viral vectors for gene silencing 
applications in cancer cells. Overall, the results of this study provided valuable 
knowledge for the design of non-viral nucleic acid vectors. 
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ANNEX I 
 
 
Figure 33 
1
H NMR spectrum of PEI in D2O. The chemical shift at 4.79 ppm corresponds to the D2O 
solvent. 
 
 
 
Figure 34 
1
H NMR spectrum of FI in DMSO. The chemical shift at 2.50 ppm corresponds to the 
DMSO solvent. 
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Figure 35 
1
H NMR spectrum of mPEG-COOH in D2O. The chemical shift at 4.79 ppm corresponds 
to the D2O solvent. 
 
 
Figure 36 
1
H NMR spectrum of NH2-PEG-COOH in D2O. The chemical shift at 4.79 ppm corresponds 
to the D2O solvent. 
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Figure 37 
1
H NMR spectrum of FA in DMSO. The chemical shift at 2.50 ppm corresponds to the 
DMSO solvent. 
Table 1 Hydrodynamic size and zeta potential of the different vector/pDNA polyplexes
a
. 
Polyplexes of vector-pDNA Hydrodynamic Size (nm) Zeta Potential (mV) 
PEI 290.67 ± 35.27 33.93 ± 2.44 
PEI-FI-mPEG 319.27 ± 12.59 42.57 ± 2.66
d
 
(Au
0
)10-PEI-FI-mPEG 223.43 ± 28.25 41.70 ± 0.88
c
 
(Au
0
)25-PEI-FI-mPEG 203.23 ± 44.42 40.27 ± 0.42
b
 
(Au
0
)50-PEI-FI-mPEG 360.90 ± 22.10 45.43 ± 0.45
d
 
PEI-FI-(PEG-FA) 164.07 ± 3.47 40.77 ± 1.48
c
 
(Au
0
)10-PEI-FI-(PEG-FA) 138.23 ± 12.24 42.23 ± 0.90
c
 
(Au
0
)25-PEI-FI-(PEG-FA) 171.10 ± 31.40 40.00 ± 1.93
b
 
(Au
0
)50-PEI-FI-(PEG-FA) 157.03 ± 4.30 41.33 ± 1.08
c
 
a
 Results are mean ± SD of three independent sample measurements. 
b
 p<0.05, when compared with PEI-pDNA polyplexes. 
c
 p<0.01, when compared with PEI-pDNA polyplexes. 
d
 p<0.001, when compared with PEI-pDNA polyplexes. 
 
Table 2 Hydrodynamic size and zeta potential of the different vector/siRNA complexes
a
. 
Complexes of vector/siRNA Hydrodynamic Size (nm) Zeta Potential (mV) 
PEI 338.43 ± 31.75 25.43 ± 1.20 
PEI-FI-mPEG 426.90 ± 52.94 25.90 ± 2.47 
(Au
0
)50-PEI-FI-mPEG 426.00 ± 22.55 23.83 ± 0.17 
PEI-FI-(PEG-FA) 420.27 ± 79.60 24.23 ± 1.47 
(Au
0
)50-PEI-FI-(PEG-FA) 260.10 ± 65.75 22.80 ± 1.50 
a
 Results are mean ± SD of three independent sample measurements.  
b
 p<0.05, when compared with PEI-siRNA complexes. 
c
 p<0.01, when compared with PEI-siRNA complexes. 
d
 p<0.001, when compared with PEI-siRNA complexes. 
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